Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients

BACKGROUND: Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we sought to describe the 5-year safety profile of maraviroc. METHODS: Two large phase 3 studies of maraviroc enrolled HIV-infected...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulick, Roy M., Fatkenheuer, Gerd, Burnside, Robert, Hardy, W. David, Nelson, Mark R., Goodrich, James, Mukwaya, Geoffrey, Portsmouth, Simon, Heera, Jayvant R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2014
Materias:
Brief Report: Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893710/
https://www.ncbi.nlm.nih.gov/pubmed/24419064
http://dx.doi.org/10.1097/QAI.0b013e3182a7a97a
_version_ 1782299739927085056
author Gulick, Roy M.
Fatkenheuer, Gerd
Burnside, Robert
Hardy, W. David
Nelson, Mark R.
Goodrich, James
Mukwaya, Geoffrey
Portsmouth, Simon
Heera, Jayvant R.
author_facet Gulick, Roy M.
Fatkenheuer, Gerd
Burnside, Robert
Hardy, W. David
Nelson, Mark R.
Goodrich, James
Mukwaya, Geoffrey
Portsmouth, Simon
Heera, Jayvant R.
author_sort Gulick, Roy M.
collection PubMed
description BACKGROUND: Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we sought to describe the 5-year safety profile of maraviroc. METHODS: Two large phase 3 studies of maraviroc enrolled HIV-infected treatment-experienced patients and followed them up for 5 or more years. Survival and selected clinical end points were identified and assessed. RESULTS: A total of 938 enrolled patients received maraviroc-containing regimens. Rates of death and selected clinical events (eg, hepatic failure, malignancy, and myocardial infarction) were low during follow-up. CONCLUSIONS: Maraviroc was generally safe in treatment-experienced participants for >5 years.
format Online
Article
Text
id pubmed-3893710
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher JAIDS Journal of Acquired Immune Deficiency Syndromes
record_format MEDLINE/PubMed
spelling pubmed-38937102014-04-15 Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients Gulick, Roy M. Fatkenheuer, Gerd Burnside, Robert Hardy, W. David Nelson, Mark R. Goodrich, James Mukwaya, Geoffrey Portsmouth, Simon Heera, Jayvant R. J Acquir Immune Defic Syndr Brief Report: Clinical Science BACKGROUND: Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we sought to describe the 5-year safety profile of maraviroc. METHODS: Two large phase 3 studies of maraviroc enrolled HIV-infected treatment-experienced patients and followed them up for 5 or more years. Survival and selected clinical end points were identified and assessed. RESULTS: A total of 938 enrolled patients received maraviroc-containing regimens. Rates of death and selected clinical events (eg, hepatic failure, malignancy, and myocardial infarction) were low during follow-up. CONCLUSIONS: Maraviroc was generally safe in treatment-experienced participants for >5 years. JAIDS Journal of Acquired Immune Deficiency Syndromes 2014-01-01 2014-01-01 /pmc/articles/PMC3893710/ /pubmed/24419064 http://dx.doi.org/10.1097/QAI.0b013e3182a7a97a Text en Copyright © 2013 by Lippincott Williams & Wilkins http://creativecommons.org/licenses/by-nc-nd/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Brief Report: Clinical Science
Gulick, Roy M.
Fatkenheuer, Gerd
Burnside, Robert
Hardy, W. David
Nelson, Mark R.
Goodrich, James
Mukwaya, Geoffrey
Portsmouth, Simon
Heera, Jayvant R.
Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
title Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
title_full Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
title_fullStr Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
title_full_unstemmed Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
title_short Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
title_sort five-year safety evaluation of maraviroc in hiv-1–infected treatment-experienced patients
topic Brief Report: Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893710/
https://www.ncbi.nlm.nih.gov/pubmed/24419064
http://dx.doi.org/10.1097/QAI.0b013e3182a7a97a
work_keys_str_mv AT gulickroym fiveyearsafetyevaluationofmaravirocinhiv1infectedtreatmentexperiencedpatients
AT fatkenheuergerd fiveyearsafetyevaluationofmaravirocinhiv1infectedtreatmentexperiencedpatients
AT burnsiderobert fiveyearsafetyevaluationofmaravirocinhiv1infectedtreatmentexperiencedpatients
AT hardywdavid fiveyearsafetyevaluationofmaravirocinhiv1infectedtreatmentexperiencedpatients
AT nelsonmarkr fiveyearsafetyevaluationofmaravirocinhiv1infectedtreatmentexperiencedpatients
AT goodrichjames fiveyearsafetyevaluationofmaravirocinhiv1infectedtreatmentexperiencedpatients
AT mukwayageoffrey fiveyearsafetyevaluationofmaravirocinhiv1infectedtreatmentexperiencedpatients
AT portsmouthsimon fiveyearsafetyevaluationofmaravirocinhiv1infectedtreatmentexperiencedpatients
AT heerajayvantr fiveyearsafetyevaluationofmaravirocinhiv1infectedtreatmentexperiencedpatients

Ejemplares similares